Fennec Pharmaceuticals Says Phase 2 Trial Of PEDMARK Met Primary Endpoint, With Hearing Loss In 24.0% Of Patients vs. Historical Benchmark Of 56.4%; Tumor Responses In 23 Of 24 Evaluable Patients